hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06335979 id: CPIT565B12101 id: 2023-510025-14-00 type: OTHER domain: EU CT briefTitle: An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). overallStatus: NOT_YET_RECRUITING date: 2024-12-16 date: 2028-08-23 date: 2028-08-23 date: 2024-03-28 date: 2024-04-11 name: Novartis Pharmaceuticals class: INDUSTRY briefSummary: The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565 in participants with SLE conditions: Systemic Lupus Erythematosus, SLE studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 54 type: ESTIMATED name: PIT565 measure: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs) measure: Maximum Observed Blood Concentrations (Cmax) measure: Time to Reach Maximum Blood Concentrations (Tmax) measure: Presence/absence of Anti-drug Antibodies sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06335966 id: STUDY00025975 briefTitle: BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy acronym: BEST-RPP overallStatus: RECRUITING date: 2024-01-25 date: 2025-01-30 date: 2025-01-30 date: 2024-03-28 date: 2024-03-28 name: OHSU Knight Cancer Institute class: OTHER name: Kuni Foundation name: Oregon Health and Science University briefSummary: Recent advancements in swallowable esophageal cell-collection devices (SECD) offer a safe, minimally invasive, accurate, and low-cost alternative to esophageal screening without the need for an upper endoscopy. The BEST-RPP study aims to evaluate the acceptability and feasibility of using this novel approach to screen for Barrett's Esophagus (BE) and Esophageal Carcinoma (EAC) in rural primary care clinic settings in Oregon. conditions: Esophageal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 110 type: ESTIMATED name: Screening with swallowable esophageal cell-collection devices (SECD) measure: Feasibility of the use of a SECD: Number of providers who indicate likelihood of using SECD measure: Feasibility of the use of SECD: Number of providers who indicate willingness to be trained and train clinic staff measure: Feasibility of the use of SECD: Number of referrals measure: Feasibility of the use of SECD: Number enrolled measure: Patient acceptability: Number of interested patients who schedule an appointment to be screened measure: Patient acceptability: Number of patients who come to their appointments measure: Patient acceptability: Number of patients interested in being screened via SECD at other care centers measure: Access: time to full diagnostic work up for patients with positive SECD results sex: MALE minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: OHSU Knight Cancer Institute status: RECRUITING city: Portland state: Oregon zip: 97239 country: United States name: Laura Ferrara, MA role: CONTACT phone: 541-399-1139 name: Fouad Otaki, MD role: PRINCIPAL_INVESTIGATOR lat: 45.52345 lon: -122.67621 hasResults: False
nctId: NCT06335953 id: IRB00418404 id: U54AG063546 type: NIH link: https://reporter.nih.gov/quickSearch/U54AG063546 briefTitle: ALIGN: Aligning Medications With What Matters Most (Demonstration) overallStatus: NOT_YET_RECRUITING date: 2024-04-18 date: 2025-04 date: 2025-04 date: 2024-03-28 date: 2024-04-22 name: Johns Hopkins University class: OTHER name: National Institute on Aging (NIA) briefSummary: The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners.
The intervention consists of the following strategies: 1) a de-prescribing educational brochure designed to activate the patient and care partner; 2) a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of the person's goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored de-prescribing recommendations designed to be useful and actionable for the PCP.
The investigators will compare the intervention group with the waitlist control group to see if there is a difference in the primary outcome, the proportion of patients who deprescribe at least one medication by 3 months. conditions: Polypharmacy conditions: Alzheimer's Disease and Related Dementias conditions: Mild Cognitive Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 280 type: ESTIMATED name: Pharmacist-led deprescribing intervention measure: Proportion of patients who stop one or more medications measure: Proportion of patients who start one or more new medications measure: Proportion of patients who stop one or more potentially inappropriate medication (PIM) measure: Total number of medications measure: Shared decision-making as assessed by CollaboRATE sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Johns Hopkins Bayview Medical Center city: Baltimore state: Maryland zip: 21224 country: United States name: Ariel Green, MD, MPH, PhD role: CONTACT phone: 410-550-6733 email: ariel@jhmi.edu lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06335940 id: 38RC23.0376 briefTitle: Admission for Respiratory Disease And VIdeo Regulation System acronym: ARAVIS-PED overallStatus: NOT_YET_RECRUITING date: 2024-04-08 date: 2024-07-31 date: 2024-10-18 date: 2024-03-28 date: 2024-04-02 name: University Hospital, Grenoble class: OTHER briefSummary: Pediatric dyspnea is a major health problem, accounting for up to 27% of admissions to emergency departments in winter. It is estimated that a significant number (13%) of patients presenting to emergency departments are outpatients, at a time when emergency departments are having to cope with an ever-increasing flow of patients.
To the best of the investigator knowledge, there is no prospective study looking at the impact of Video-Regulation on the outcome of patients requiring the advice of SAMU Centre-15 for pediatric dyspnea. conditions: Pediatric Respiratory Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 588 type: ESTIMATED name: Videoregulation measure: To determine in children under 10 years of age for whom a call to the SAMU38 for dyspnea is made, whether the use of Visio-Regulation reduces the percentage of emergency room admissions compared with standard telephone medical regulation. measure: Evaluate whether the use of video-regulation has an impact on the dispatcher's referral decision between ambulatory medicine and the emergency department. measure: Determine whether the use of video-regulation leads to an increase in call time with the regulating doctor measure: Evaluate parents' satisfaction with videoregulation compared with a standard call measure: Evaluate the number of rescue vectors (fire brigade, private ambulance) triggered but whose decision will ultimately be to "leave on the spot" after the rescue worker's assessment. measure: Evaluate whether the increased use of video-regulation is not associated with a higher rate of hospitalization in a conventional ward or intensive care unit sex: ALL maximumAge: 10 Years stdAges: CHILD hasResults: False
nctId: NCT06335927 id: GWK2023-001 briefTitle: HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC overallStatus: RECRUITING date: 2023-05-11 date: 2025-05-10 date: 2026-05-10 date: 2024-03-28 date: 2024-03-28 name: Fudan University class: OTHER briefSummary: This study is a single-arm Phase II clinical trial aiming to evaluate the safety and efficacy of HAIC combined with Cadonilimab and Regorafenib as second-line treatment for unresectable intrahepatic cholangiocarcinoma.
The study plans to enroll approximately 45 participants. All enrolled participants will receive continuous treatment: HAIC-Gemox: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles, Cadonilimab(6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W) until the investigator determines that there is no longer any clinical benefit (based on comprehensive assessment including RECIST v1.1 imaging evaluation and clinical condition), intolerable toxicity, initiation of new anti-tumor therapy, or meeting other criteria for treatment discontinuation, whichever occurs first. conditions: Intrahepatic Cholangiocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: HAIC-GEMOX+Cadonilimab+Regorafenib measure: Objective Response Rate (ORR) measure: Hepatic Objective Response Rate (hORR) measure: Duration of Response (DoR) measure: Disease Control Rate (DCR) measure: Time to Response (TTR) measure: Progression-Free Survival (PFS) measure: Overall Survival (OS) measure: Safety and tolerability sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center status: RECRUITING city: Shanghai state: Shanghai zip: 200032 country: China name: Li Tan role: CONTACT phone: +8615800680751 lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06335914 id: dualPET-mPC id: CAPCR: 23-5595 type: OTHER domain: University Health Network briefTitle: Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2029-03-04 date: 2029-09-04 date: 2024-03-28 date: 2024-03-28 name: University Health Network, Toronto class: OTHER briefSummary: This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future. conditions: Advanced Prostate Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ESTIMATED name: Ga 68 PSMA-11 PET name: 18F-DCFPyL PET name: FDG PET measure: Proportion of patients with high volume mCSPC having PSMA avid disease measure: Proportion of patients with PSMA-/FDG+ discordant lesions sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Princess Margaret Cancer Centre city: Toronto state: Ontario zip: M5G 2M9 country: Canada name: Di (Maria) Jiang, M.D. role: CONTACT phone: 416-946-4501 phoneExt: 4807 email: di.jiang@uhn.ca name: Di (Maria) Jiang, M.D. role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06335901 id: xx20190901 briefTitle: Clinical Characteristics and Outcomes of Coronary Heart Disease overallStatus: COMPLETED date: 2020-02-01 date: 2022-01-31 date: 2022-04-30 date: 2024-03-28 date: 2024-03-29 name: Xinjiang Medical University class: OTHER briefSummary: This study evaluated and compared the prognostic value of different Baseline data and clinical variables to develop a risk ractor ediction model in patients with CHD. conditions: Coronary Heart Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20000 type: ACTUAL name: Drug:Standard therapy measure: Death （All-cause mortality、Cardiac mortality ） measure: Major adverse cardiovascular events sex: ALL minimumAge: 18 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Xinjiang Medical University city: Ürümqi state: Xinjiang zip: 630000 country: China lat: 43.80096 lon: 87.60046 hasResults: False
nctId: NCT06335888 id: CRAFT briefTitle: A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis acronym: CRAFT overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2029-05 date: 2029-05 date: 2024-03-28 date: 2024-04-05 name: Insel Gruppe AG, University Hospital Bern class: OTHER name: Paul Scherrer Institut, Center for Proton Therapy briefSummary: The goal of this open-label clinical trial is to evaluate the efficacy of AzaFol-PET/CT in the diagnosis of GCA (giant cell arteritis), to compare AzaFol- with 2-\[18F\]FDG-PET/CT, and to assess the safety and tolerability of AzaFol in subjects with suspicion of GCA.
Participants will undergo AzaFol-PET/CT imaging at a single timepoint. conditions: Giant Cell Arteritis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Cross-over, randomized, open label, single-centre primaryPurpose: DIAGNOSTIC masking: NONE count: 70 type: ESTIMATED name: AzaFol name: FDG measure: Specificity of the GCA-diagnosis at the patient level measure: Lesion detection rate (visual analysis) measure: Lesion detection rate (semiquantitative analysis) measure: Sensitivity of the GCA-diagnosis at the patient level sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Rheumatology and Immunology, University Hospital Bern, Inselspital city: Bern zip: 3010 country: Switzerland name: Britta Maurer role: CONTACT lat: 46.94809 lon: 7.44744 hasResults: False
nctId: NCT06335875 id: HUM00227568 briefTitle: Brain Small Chain Fatty Acid Metabolism in Bipolar Disorder: Ketones acronym: BIPO overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2027-03 date: 2027-03 date: 2024-03-28 date: 2024-03-28 name: University of Michigan class: OTHER briefSummary: Small exploratory open-label pilot study to assess supplementation of a ketone ester (Juvenescence) combined with a 'ketogenic-mimicking diet' as a potential therapy for persons with bipolar disorder. conditions: Bipolar Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Ketone Ester Beverage name: Low Glycemic Index Diet measure: Change in blood beta-hydroxybutyrate level measure: Change in blood glucose lability measure: Change in neural network stability sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Domino's Farms city: Ann Arbor state: Michigan zip: 48105 country: United States lat: 42.27756 lon: -83.74088 facility: University Hospital city: Ann Arbor state: Michigan zip: 48109 country: United States lat: 42.27756 lon: -83.74088 hasResults: False
nctId: NCT06335862 id: NL.84862.041.23 briefTitle: Primary Posterior Tracheopexy Prevents Tracheal Collapse acronym: PORTRAIT overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-09-30 date: 2027-03-31 date: 2024-03-28 date: 2024-03-28 name: UMC Utrecht class: OTHER name: For Wis(h)dom Foundation name: Erasmus Medical Center name: Great Ormond Street Hospital for Children NHS Foundation Trust name: Karolinska University Hospital briefSummary: Introduction: Children born with a blind-ending gullet (oesophagus), or Oesophageal Atresia (OA), need to undergo surgical correction in the first week of life. OA is often accompanied by a weakened windpipe (trachea), known as tracheomalacia (TM). TM entails that the windpipe collapses during expiration. Severe TM can cause respiratory symptoms, including frequent respiratory tract infections and blue spells, that can potentially lead to life-threatening events. In some patients, major secondary surgical treatment may be indicated. This surgical procedure involves widening the trachea (using sutures) to prevent collapse, known as secondary posterior tracheopexy (SPT). Prior to performing this SPT, complications and negative consequences of TM may have already occurred. This may be prevented by performing this procedure during the primary OA correction, called a primary posterior tracheopexy (PPT). The aim of this trial is to determine if a PPT can decrease - or prevent - tracheal collapse in newborns with OA and TM, compared to a wait-and-see policy (no-PPT).
Methods: This is an international multicentre double-blind randomised controlled trial. Seventy eight children with OA type C will be included. Patients will be included after written parental informed consent. Half of the patients will be randomly allocated to the PPT-group and half to the no-PPT-group. The degree and location of TM are evaluated through preoperative, intraoperative and two postoperative videoscopic examinations of the trachea (tracheobronchoscopy). Whether TM symptoms occur is assessed during three routine follow-up consultations until the age of 6 months. The primary outcome is the degree of collapse of the tracheal wall during the intraoperative tracheobronchoscopy (after performing the PPT/no-PPT), measured in percentages.
Risks and burden: Since OA correction with PPT (more recently implemented in centres of expertise) and without PPT (wait-and-see policy) are both accepted and safe treatment options, participating in the trial does not pose an increased risk or burden with regards to the treatment. Performing tracheobronchoscopies may pose a potential burden. However, a tracheobronchoscopy is a routine diagnostic procedure commonly used to safely assess the trachea. Complications of a tracheobronchoscopy are rare. Also, many of the tracheobronchoscopies are routinely performed as part of standard care for these patients, regardless of the trial. conditions: Oesophageal Atresia With Tracheo-Oesophageal Fistula conditions: Tracheomalacia conditions: Oesophageal Atresia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients will be randomized 1:1 into either the intervention group (PPT-group) or the wait-and-see group (no-PPT). Since the sutures of the PPT remain in place (in the PPT-group), the participants are allocated to one arm for the duration of the study. After the PPT was or was not performed, the participants will follow the same follow-up schedule. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: All participants, parents/caregivers, investigators and treating healthcare personnel, except for the surgical team performing the OA correction, will be blinded to which study arm the participant is assigned. None of the data gathered is affected by the unblinded surgical team since the primary and key secondary outcome measures are evaluated based on pseudonymised video footage. Furthermore, this video footage is assessed by otolaryngologists who are blinded to the patient and study arm. Moreover, the follow-up and documentation of the secondary endpoints are typically performed by the paediatrician and speech- and language therapists (not the paediatric surgeon or otolaryngologist). whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 78 type: ESTIMATED name: Randomisation between the PPT- and no-PPT-group name: Primary Posterior Tracheopexy name: Preoperative tracheobronchoscopy name: Intraoperative tracheobronchoscopy name: Postoperative tracheobronchoscopy through the endotracheal tube during extubation name: Postoperative tracheobronchoscopy after 2-6 months measure: Difference in degree of TM between the PPT-group and no-PPT-group during intraoperative tracheobronchoscopy measure: Key secondary outcome: Difference in degree of TM between the PPT-group and no-PPT-group during postoperative tracheobronchoscopy measure: Difference in symptoms between the PPT-group and no-PPT-group measure: Degree of preoperative TM compared to postoperative TM sex: ALL minimumAge: 34 Weeks stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06335849 id: LYB004-CT-AUS-101 briefTitle: A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-02 date: 2025-05 date: 2024-03-28 date: 2024-03-28 name: Guangzhou Patronus Biotech Co., Ltd. class: INDUSTRY name: Yantai Patronus Biotech Co., Ltd. briefSummary: This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years. conditions: Herpes Zoster studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: LYB004 25µg name: LYB004 50µg name: SHINGRIX measure: Evaluate the reactogenicity of LYB004 vaccine measure: Evaluate the safety and reactogenicity of LYB004 vaccine measure: Evaluate the safety of LYB004 vaccine measure: Evaluate the safety and tolerability in laboratory tests of LYB004 vaccine measure: Evaluate the SAEs and AESIs of LYB004 vaccine measure: Observe the humoral immunity of LYB004 vaccine measure: Observe the cellular immunity of LYB004 vaccine measure: Observe the persistence of humoral immunity of LYB004 vaccine measure: Observe the persistence of cellular immunity of LYB004 vaccine sex: ALL minimumAge: 50 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nucleus Network Pty Ltd city: Melbourne state: Victoria zip: 3004 country: Australia name: Katherine Gunn role: CONTACT phone: (07) 3707 2781 email: k.gunn@nucleusnetwork.com.au name: Kristof Boot role: CONTACT phone: (07) 3707 2780 email: k.boot@nucleusnetwork.com.au name: Christina Chang, M.D. role: PRINCIPAL_INVESTIGATOR lat: -37.814 lon: 144.96332 hasResults: False
nctId: NCT06335836 id: 2024-SR-127 id: 2024-SR-127 type: OTHER domain: Ethics Committee of Nanjing Medical University briefTitle: The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD) overallStatus: RECRUITING date: 2024-03-01 date: 2028-12-30 date: 2028-12-30 date: 2024-03-28 date: 2024-03-28 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD
4. Confirm the protective effect of social interaction on cognitive level and brain function in SCD patients. conditions: Social Isolation conditions: SCD conditions: Subjective Cognitive Decline conditions: MCI conditions: Mild Cognitive Impairment conditions: AD conditions: Alzheimer Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 209 type: ESTIMATED name: social isolation measure: Incidence of Mild Cognitive Impairment (MCI) measure: Incidence of Alzheimer's disease (AD) measure: AVLT-H measure: MoCA measure: WMS-RLM measure: WDS measure: VFT measure: BNT measure: LSNS-6 measure: UCLA measure: GDS measure: PSQI measure: DTC measure: fMRI measure: tau measure: Aβ measure: APOE genotyping measure: TMT-A, TMT-B sex: ALL minimumAge: 45 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: China, Jiangsu zip: 210000 country: China name: Zhu Yi role: CONTACT phone: +86 137 0516 4030 email: ZhuYi1981@njmu.edu.cn name: Shi Chunxu role: CONTACT phone: +8618625175592 email: scx_0212@outlook.com lat: 32.06167 lon: 118.77778 hasResults: False